GlassScriptPhysician profile
Naushad Pervez
NPI 1962403170
$5,697.08
in general payments reported to CMS, 2019-2025
34 companies · $959 in 2025
The $959 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $331 · 2021: $596 · 2022: $767 · 2023: $927 · 2024: $1,394 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.71 |
| Education | $100.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,432.73 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $495.92 | 2019-2023 | Veltassa, Korsuva |
| Amgen INC. | $484.25 | 2019-2025 | Tavneos, Krystexxa |
| Ani Pharmaceuticals, INC. | $397.92 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $317.08 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $274.29 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.76 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $194.73 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $189.04 | 2019-2025 | Ultomiris |
| Ardelyx, INC. | $179.33 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $173.63 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $145.97 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $133.52 | 2022-2024 | Lupkynis |
| Akebia Therapeutics INC | $116.59 | 2019-2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $109.85 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $108.74 | 2021-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $106.80 | 2022-2025 | Tarpeyo |
| Exact Sciences Corporation | $93.39 | 2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $76.51 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $57.28 | 2025 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $56.08 | 2021-2022 | |
| Shield Therapeutics INC | $37.72 | 2023 | Accrufer |
| Lilly USA, LLC | $33.56 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $32.64 | 2021-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $29.45 | 2024 | Jynarque |
| Pharmacosmos Therapeutics INC. | $20.97 | 2022 | |
| Chiesi USA, INC. | $20.72 | 2025 | Elfabrio |
| Vantive US Healthcare LLC | $19.74 | 2025 | Renal - Pd |
| Scpharmaceuticals INC. | $19.34 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.48 | 2025 | Edarbi |
| Genzyme Corporation | $17.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.74 | 2023 | Gattex |
| Ultragenyx Pharmaceutical INC. | $14.21 | 2022 | |
| Shire North American Group INC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naushad Pervez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.